INDUSTRIAL IMPACT, MEDICAL
Businesswire | April 24, 2023
Guardant Health, Inc. a leading precision oncology company, is pleased to announce that it will present data from two studies highlighting the performance of its blood-based screening technology to detect early-stage colorectal cancer (CRC), including the acceptance of the ECLIPSE study as a late-breaking abstract, at Digestive Disease Week (DDW) taking place in Chicago, Illinois on May 6-9, 2023.
“Despite multiple screening modalities for colorectal cancer, screening rates remain stubbornly low leaving many cancers undetected. A blood test that can accurately detect CRC represents a significant opportunity to overcome some of the known challenges with patient adherence,” said AmirAli Talasaz, Guardant Health co-CEO. “We are thrilled that DDW has accepted the ECLIPSE study, one of the largest studies of its kind, as a late-breaking abstract, and we look forward to sharing this new data with the healthcare community at this year’s meeting.”
“The need for a convenient, less invasive way to screen for CRC is great, and an accurate blood test can play a critical role in improving screening rates, especially for those reluctant to get screened,” said Daniel Chung, MD, gastroenterologist at Massachusetts General Hospital and Professor of Medicine at Harvard Medical School. “I look forward to presenting at DDW and sharing new data from the ECLIPSE Study on the performance and potential of the Shield blood test to help improve adherence to screening."
About Guardant Health
Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched Guardant360®, Guardant360 CDx, Guardant360 TissueNext™, Guardant360 Response™, and GuardantINFINITY™ tests for advanced-stage cancer patients, and Guardant Reveal™ for early-stage cancer patients. The Guardant Health screening portfolio, including the commercially launched Shield™ test, aims to address the needs of individuals eligible for cancer screening.
CELL AND GENE THERAPY, INDUSTRIAL IMPACT
Center for Breakthrough Medicines | February 27, 2023
Center for Breakthrough Medicines (CBM), a leading contract development and manufacturing organization dedicated to addressing the challenges of commercializing cell and gene therapies, and Virion Therapeutics, a clinical-stage biotech firm focused on developing accessible and adaptable CD8+ T cell-based technologies for cancer and infectious diseases, have recently announced a strategic collaboration agreement.
CBM will partner and manufacture with Virion Therapeutics on their checkpoint modifier clinical development programs, including the First-in-Human VRON-0200 immunotherapy, designed to treat chronic Hepatitis B Virus (HBV) infection.
The collaboration aims to develop VRON-0200, a pan-genotypic, global therapeutic immunotherapy that targets chronic HBV infection, which affects over 295 million people worldwide. HBV impairs CD8+ T cells, which results in the loss of viral control. VRON-0200 induces a broad CD8+ T cell response, which includes responses to the core and pol regions not generally induced by the infection. Therefore, VRON-0200 is designed to stimulate a highly functional immune response to help clear the virus.
CBM's Co-Founder and Chief Business Officer Audrey Greenberg commented, "Virion is working to revolutionize the immunotherapy treatment landscape, and we are honored to partner with them on this bold mission as we share a common goal – to create a future free of cancer and chronic infectious diseases." She further emphasized, "We have assembled best-in-field technical teams, supported by industry-leading product and process development, manufacturing, and testing capabilities, all located within a single, world-class manufacturing facility. We look forward to working with Virion to bring their life-saving therapies to the patients who need them most, as quickly as possible."
(Source – PR Newswire)
About Center for Breakthrough Medicines
The Center for Breakthrough Medicines is a pioneering contract development and manufacturing organization (CDMO) situated in the center of "Cellicon Valley," with a focus on cell and gene therapies. It offers an all-in-one solution to expedite the speed of delivering advanced treatments to the market. Its customer-oriented approach, combined with a culture that prioritizes the needs of patients, guarantees dependable and high-quality process and analytical development, GMP testing, viral vector manufacturing, plasmid production, cell therapy bioprocessing and cell banking services throughout the entire life cycle of a product.
MEDTECH, INDUSTRIAL IMPACT
SOPHiA GENETICS and QIAGEN | March 06, 2023
SOPHiA GENETICS, a healthcare cloud-based software company, announced a new partnership with QIAGEN N.V. that will pair QIAseq reagent technology with the SOPHiA DDM™ platform to improve tumor analysis via next-generation sequencing (NGS).
Customers can utilize QIAseq panels with SOPHiA DDM™, a cloud-based data analysis platform to enable new research perspectives. The partnership will support the detection of somatic variants using QIAseq targeted DNA pro panels for homologous recombination repair. HRR is a biomarker test that helps identify tumors with specific mutations that may be sensitive to PARP inhibitors in oncology.
SOPHiA GENETICS's Set-Up Program, which aims to establish and demonstrate any test's analytical performance before it is carried out, will be integrated with QIAGEN's kits to support a range of applications. This partnership will allow customers to improve the design of new workflows using QIAseq technologies, while SOPHiA DDM™ will offer extensive applications for QIAGEN kits.
QIAGEN intends to expand its partnership with SOPHiA GENETICS to other analysis areas, such as utilizing custom solutions and QIAseq panels. This partnership is the first one in QIAGEN's QIAseq Platform Partnership.
Next-generation sequencing (NGS) can transform the detection and management of rare diseases and cancers. However, it also generates large, intricate, and messy datasets that are challenging to analyze. Identifying causal variants and getting valuable insights from NGS data requires specialized expertise, time, and numerous resources. The SOPHiA DDM™ Platform is a machine learning-based analytical tool that can efficiently call, annotate, and pre-classify variants from raw NGS data. In addition, it features user-friendly capabilities to facilitate prioritization, interpretation and reporting.
QIAGEN is a global provider of sample and assay technologies for academic and pharmaceutical research, molecular diagnostics, and applied tests. In addition, the firm offers a wide range of products and solutions for the isolation, purification, and analysis of DNA, RNA, and proteins, as well as automation and bioinformatics services. With over 35 countries and over 5,000 employees, QIAGEN serves customers in various fields such as human healthcare, animal health, and environmental testing. The company is headquartered in Venlo, Netherlands, and has offices and facilities across the globe.